Nutra Pharma Corp. reported its financial results for the third quarter ending September 30, 2023, revealing a significant increase in revenue compared to the same period last year. The company generated net sales of $51,612 for the three months ended September 30, 2023, up from $24,624 in the prior year, marking a 109% increase. For the nine-month period, net sales reached $158,532, compared to $66,814 in the same timeframe in 2022. Despite this growth in revenue, Nutra Pharma reported a net loss of $278,486 for the quarter and a net loss of $1,150,292 for the nine months, a decline from a net income of $577,229 for the third quarter of 2022.
The company's financial position showed a total asset value of $711,338 as of September 30, 2023, down from $754,913 at the end of 2022. Current liabilities increased to $13,950,631 from $12,700,821, contributing to a stockholders' deficit of $13,525,244, compared to $12,377,452 at the end of the previous fiscal year. The increase in liabilities was primarily driven by higher accrued expenses and accounts payable, which rose to $1,824,312 and $752,477, respectively.
Operationally, Nutra Pharma has continued to focus on its product offerings, which include pain relief medications such as Cobroxin® and Nyloxin®. The company has also engaged in strategic financing activities, including loans from officers and proceeds from convertible notes, to support its operations. The company reported a working capital deficit of $13,586,792, indicating ongoing challenges in maintaining liquidity. As of September 30, 2023, Nutra Pharma had no cash on hand, highlighting the need for additional financing to sustain operations.
Looking ahead, Nutra Pharma's management expressed concerns regarding the company's ability to continue as a going concern, citing the need for additional financing to execute its operating plan and achieve profitability. The company is currently exploring options to secure funding through debt and equity, but faces challenges due to its stock being listed on the OTC Market Group’s Expert Market, which limits its ability to raise capital. The management's outlook remains cautious, as the company must navigate a competitive market environment while addressing its financial obligations and operational needs.
About NUTRA PHARMA CORP
Nutra Pharma is a biopharmaceutical company specializing in drug discovery, development, and commercialization of treatments for autoimmune, viral, and pain-related conditions. It offers over-the-counter pain relievers, homeopathic products, and drug candidates targeting neurological and infectious diseases. The company focuses on innovative therapies, strategic licensing, and international expansion, leveraging proprietary technology and regulatory designations like Orphan Drug status to address serious health conditions.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov